Dapiprazole
Modify Date: 2025-08-21 16:44:07
Dapiprazole structure
|
Common Name | Dapiprazole | ||
|---|---|---|---|---|
| CAS Number | 72822-12-9 | Molecular Weight | 325.451 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 538.9±60.0 °C at 760 mmHg | |
| Molecular Formula | C19H27N5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 279.7±32.9 °C | |
Use of DapiprazoleDapiprazole is a potent, selective and orally active alpha-1 adrenoceptor antagonist. Dapiprazole suppresses the opioid withdrawal symptoms. Dapiprazole is also used as eye drops for reversing mydriasis[1][2][3]. |
| Name | dapiprazole |
|---|---|
| Synonym | More Synonyms |
| Description | Dapiprazole is a potent, selective and orally active alpha-1 adrenoceptor antagonist. Dapiprazole suppresses the opioid withdrawal symptoms. Dapiprazole is also used as eye drops for reversing mydriasis[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
α1-adrenergic receptor |
| In Vivo | Dapiprazole hydrochloride (0-10 mg/kg or 0-3 mg/mice; i.p. or i.c.v.; once) reduces the overall severity of the opiate withdrawal symptoms in mice[1]. Animal Model: Swiss Albino male CD-1 mice weighing 20 -25 g, acute dependence model (mice were injected i.p. with morphine (25 mg/kg) and 2 h later with naloxone (12.5 mg/kg))[1] Dosage: 5, 7.5 and 10 mg/kg (i.p.) or 0.5, 1 and 3 mg/mice (i.c.v.), once Administration: Intraperitoneal injection or intracerebroventricular administration, once Result: Decreased jumping behavior, head shakes and paw shakes when administered just before naloxone. Resulted in a notable suppression of morphine withdrawal symptoms in a dose-related fashion when injected i.c.v.. |
| References |
[2]. Allinson RW, et al. Reversal of mydriasis by dapiprazole. Ann Ophthalmol. 1990 Apr;22(4):131-3, 138. |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 538.9±60.0 °C at 760 mmHg |
| Molecular Formula | C19H27N5 |
| Molecular Weight | 325.451 |
| Flash Point | 279.7±32.9 °C |
| Exact Mass | 325.226654 |
| PSA | 37.19000 |
| LogP | 2.44 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.658 |
| InChIKey | RFWZESUMWJKKRN-UHFFFAOYSA-N |
| SMILES | Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Total 173, Current Page 1 of 18
1
2
3
4
5
| Rev-Eyes |
| 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine |
| 5,6,7,8-Tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]-1,2,4-triazolo[4,3-a]pyridine |
| Dapiprazole |
| Dapiprazol [German] |
| Dapirazol |
| Glamidolo |
| 3-{2-[4-(2-Methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine |
| 3-[2-(4-o-tolyl-piperazin-1-yl)-ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine |
| 3-{2-[4-(2-Methylphenyl)-1-piperazinyl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine |
| 5,6,7,8-Tetrahydro-3-[2-(4-o-tolyl-1-piperazinyl)ethyl]-s-triazolo[4,3-a]pyridine |
| 5,6,7,8-tetrahydro-3-[2-(4-o-tolyl-1-piperazin)ethyl]-1,2,4-triazolo[4,3-a]pyridine |
| Reversil |
| Dapiprazole [INN] |
| Dapiprazol |
| dapiprazolum |
| Dapirazolum |